Device that automatically detects opioid overdose and delivers antidote naloxone to reverse it's effects was developed by Purdue University researchers.
"The antidote is always going to be with you," said Hyowon "Hugh" Lee, an assistant professor of biomedical engineering at Purdue. "The device wouldn't require you to recognize that you're having an overdose or to inject yourself with naloxone, keeping you stable long enough for emergency services to arrive."
Concerns on Commonly Used Opioid Antidote Naloxone Formulation
Patients, families, friends and emergency responders lack enough knowledge about the safety and effectiveness of widespread off-label use of naloxone.
Advertisement
‘Novel wearable device helps opioid abusers who are mostly alone and incapicated by automatically delivering the antidote naloxone within 10 seconds.’
Tweet it Now
Overdose happens when opioids bind to receptors in the brain that regulate breathing, causing a person to hypoventilate and die. According the U.S. Department of Health and Human Services, approximately 130 people in the U.S. die every day from opioid-related drug overdoses.
Lee's team has built a wearable device designed to detect when a person's respiration rate decreases to a certain level - converted from electrocardiography (EKG) signals - and then release naloxone, which blocks the opioid from binding to brain receptors.
Wearing the device would be similar to wearing an insulin pump: The current proof of concept is an armband that straps on a magnetic field generator, connected to a portable battery worn at the hip. A sticker-like EKG sensor on the skin, such as on the chest, measures respiration rate. When the sensor detects a respiration rate that's too low, it activates the magnetic field generator to heat up a drug capsule in the body, releasing naloxone in 10 seconds.
The researchers envision the drug capsule being pre-injected under the skin in an outpatient setting. That way, the device system would automatically deliver naloxone to the patient during an overdose, buying about an hour before relapsing.
According to Lee, that extra hour would give emergency services plenty of time to get the patient to the hospital. The capsule also delivers a larger dose of naloxone than products currently available on the market - making it more effective at delaying relapse - and would be cheaper to manufacture.
Although the device doesn't yet work automatically, the researchers demonstrated through in vitro and in vivo experiments that the setup successfully detects a low respiration rate from EKG signals and delivers naloxone. Their work appears in the Journal of Controlled Release.
The device has been patented through the Purdue Research Foundation Office of Technology Commercialization. Since submitting the work for publication, the researchers have downsized the magnetic field generator and battery so that the device is less bulky.
"The goal is to make the whole system unobtrusive, so that you don't feel like you're having to wear something large all the time," Lee said.
The researchers also plan to build a communications system into the device that would automatically alert emergency services when the patient has overdosed.
The technology could possibly deliver other drugs besides naloxone.
"People with allergies need epinephrine right away. This setup might remove the need for an epi pen," Lee said.
Source: Eurekalert
Advertisement
Wearing the device would be similar to wearing an insulin pump: The current proof of concept is an armband that straps on a magnetic field generator, connected to a portable battery worn at the hip. A sticker-like EKG sensor on the skin, such as on the chest, measures respiration rate. When the sensor detects a respiration rate that's too low, it activates the magnetic field generator to heat up a drug capsule in the body, releasing naloxone in 10 seconds.
The researchers envision the drug capsule being pre-injected under the skin in an outpatient setting. That way, the device system would automatically deliver naloxone to the patient during an overdose, buying about an hour before relapsing.
According to Lee, that extra hour would give emergency services plenty of time to get the patient to the hospital. The capsule also delivers a larger dose of naloxone than products currently available on the market - making it more effective at delaying relapse - and would be cheaper to manufacture.
Although the device doesn't yet work automatically, the researchers demonstrated through in vitro and in vivo experiments that the setup successfully detects a low respiration rate from EKG signals and delivers naloxone. Their work appears in the Journal of Controlled Release.
The device has been patented through the Purdue Research Foundation Office of Technology Commercialization. Since submitting the work for publication, the researchers have downsized the magnetic field generator and battery so that the device is less bulky.
"The goal is to make the whole system unobtrusive, so that you don't feel like you're having to wear something large all the time," Lee said.
The researchers also plan to build a communications system into the device that would automatically alert emergency services when the patient has overdosed.
The technology could possibly deliver other drugs besides naloxone.
"People with allergies need epinephrine right away. This setup might remove the need for an epi pen," Lee said.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.